solid tumours

News

Hong Kong biopharma company Akeso has secured clinical trial clearance in China for a next-generation antibody-drug conjugate (ADC) targeting B7-H3.

News

Akiram & ITM sign supply agreement for Lutetium-177 to support development of targeted antibody-radionuclide conjugate AKIR001 in solid tumours.

Oncology

Circulating tumour DNA (ctDNA) has emerged as a promising primary surrogate endpoint in solid tumour oncology.

Oncology

CAR-NK cell therapies are frequently misunderstood, despite growing clinical and preclinical data supporting their potential.

Oncology

In a new podcast, Intensity Therapeutics' Lew Bender discusses intra-tumourally injected therapeutics - a novel approach to cancer cell death.

Oncology

What if we could reprogramme the TME itself? Cutting-edge research suggests that engineered mesenchymal stem cells (MSCs) could disrupt this shield.